Search research articles
Contact Us
Filters
Showing results (51-60 of 64) with videos related to
Page
of 7
Sort By:
Current Therapeutic Research, Clinical and Experimental
|
December 1, 2025
The Effects of Fasinumab on Peripheral Nerve Function and Ganglion Anatomy: Results From a Randomized, Double-Blind, Placebo-Controlled Study in Patients With Pain Due to Osteoarthritis of the Knee or Hip, and a Series of Nonclinical Studies
Simon Eng, Michael Fetell, Haitao Gao, et al.
Cancer Treatment and Research Communications
|
July 23, 2025
Peripheral blood cells as prognostic markers in patients with advanced non-small cell lung cancer treated with cemiplimab as monotherapy or in combination with chemotherapy
Rolando J Acosta, Debra A G McIntyre, Joseph C Murray, et al.
Viruses
|
July 2, 2021
Successful Clearance of 300 Day SARS-CoV-2 Infection in a Subject with B-Cell Depletion Associated Prolonged (B-DEAP) COVID by REGEN-COV Anti-Spike Monoclonal Antibody Cocktail
Arnaud C Drouin, Marc W Theberge, Sharon Y Liu, et al.
Journal of the American College of Cardiology
|
September 4, 2024
Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome
Doron Zahger, Gregory G Schwartz, Weiming Du, et al.
Osteoarthritis and Cartilage Open
|
January 16, 2026
Identification of alkaline phosphatase as a putative biomarker of anti-NGF treatment-associated arthropathies: Machine learning-assisted analyses of clinical trial data
Matthew F Wipperman, Peter J Ehmann, Debra A G McIntyre, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 8, 2020
Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants
Eric A F Simões, Eduardo Forleo-Neto, Gregory P Geba, et al.
BMJ Open
|
October 9, 2024
Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 study
Thomas D Norton, Mazhar Thakur, Samit Ganguly, et al.
Journal of the Pediatric Infectious Diseases Society
|
October 1, 2024
Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19
Thomas D Norton, Mazhar Thakur, Samit Ganguly, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|
July 5, 2022
Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19
Flonza Isa, Eduardo Forleo-Neto, Jonathan Meyer, et al.
JAMA Network Open
|
August 15, 2022
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial
Cynthia Portal-Celhay, Eduardo Forleo-Neto, Will Eagan, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 64) with videos related to
Sort By:
Page
of 7
Current Therapeutic Research, Clinical and Experimental
|
December 1, 2025
The Effects of Fasinumab on Peripheral Nerve Function and Ganglion Anatomy: Results From a Randomized, Double-Blind, Placebo-Controlled Study in Patients With Pain Due to Osteoarthritis of the Knee or Hip, and a Series of Nonclinical Studies
Simon Eng, Michael Fetell, Haitao Gao, et al.
Cancer Treatment and Research Communications
|
July 23, 2025
Peripheral blood cells as prognostic markers in patients with advanced non-small cell lung cancer treated with cemiplimab as monotherapy or in combination with chemotherapy
Rolando J Acosta, Debra A G McIntyre, Joseph C Murray, et al.
Viruses
|
July 2, 2021
Successful Clearance of 300 Day SARS-CoV-2 Infection in a Subject with B-Cell Depletion Associated Prolonged (B-DEAP) COVID by REGEN-COV Anti-Spike Monoclonal Antibody Cocktail
Arnaud C Drouin, Marc W Theberge, Sharon Y Liu, et al.
Journal of the American College of Cardiology
|
September 4, 2024
Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome
Doron Zahger, Gregory G Schwartz, Weiming Du, et al.
Osteoarthritis and Cartilage Open
|
January 16, 2026
Identification of alkaline phosphatase as a putative biomarker of anti-NGF treatment-associated arthropathies: Machine learning-assisted analyses of clinical trial data
Matthew F Wipperman, Peter J Ehmann, Debra A G McIntyre, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 8, 2020
Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants
Eric A F Simões, Eduardo Forleo-Neto, Gregory P Geba, et al.
BMJ Open
|
October 9, 2024
Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 study
Thomas D Norton, Mazhar Thakur, Samit Ganguly, et al.
Journal of the Pediatric Infectious Diseases Society
|
October 1, 2024
Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19
Thomas D Norton, Mazhar Thakur, Samit Ganguly, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|
July 5, 2022
Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19
Flonza Isa, Eduardo Forleo-Neto, Jonathan Meyer, et al.
JAMA Network Open
|
August 15, 2022
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial
Cynthia Portal-Celhay, Eduardo Forleo-Neto, Will Eagan, et al.
Page
of 7